Nyxoah S.A. (NASDAQ:NYXH) Short Interest Update

Nyxoah S.A. (NASDAQ:NYXH - Get Free Report) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 100,200 shares, a growth of 27.2% from the February 13th total of 78,800 shares. Based on an average trading volume of 43,000 shares, the short-interest ratio is currently 2.3 days. Approximately 0.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Nyxoah in a report on Friday, December 13th. Stifel Nicolaus decreased their price objective on shares of Nyxoah from $16.00 to $15.00 and set a "buy" rating for the company in a report on Friday, March 14th.

Nyxoah Price Performance

NASDAQ:NYXH traded down $0.16 during trading hours on Friday, reaching $11.31. 14,598 shares of the company's stock were exchanged, compared to its average volume of 44,477. The company has a market capitalization of $385.22 million, a P/E ratio of -6.05 and a beta of 1.42. Nyxoah has a 12 month low of $6.76 and a 12 month high of $15.79. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The business's 50-day simple moving average is $10.38 and its two-hundred day simple moving average is $9.25.

Nyxoah (NASDAQ:NYXH - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). The business had revenue of $1.35 million for the quarter, compared to the consensus estimate of $2.02 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%. Sell-side analysts expect that Nyxoah will post -1.91 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Nyxoah

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kovack Advisors Inc. acquired a new position in Nyxoah in the 3rd quarter worth approximately $96,000. LPL Financial LLC acquired a new position in Nyxoah in the 4th quarter worth approximately $102,000. Walleye Capital LLC boosted its stake in Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock worth $119,000 after purchasing an additional 2,862 shares during the period. Ameriprise Financial Inc. acquired a new position in Nyxoah in the 4th quarter worth approximately $135,000. Finally, Geode Capital Management LLC boosted its stake in Nyxoah by 19.4% in the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after purchasing an additional 2,774 shares during the period.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.